Blar i Faculty of Medicine på forfatter "Bringeland, Gerd Haga"

Viser treff 1-7 av 7

    • Candidate markers for stratification and classification in rheumatoid arthritis 

      Bader, Lucius; Gullaksen, Stein-Erik; Blaser, Nello; Brun, Morten; Bringeland, Gerd Haga; Sulen, Andre; Gjesdal, Clara Gram; Vedeler, Christian A.; Gavasso, Sonia (Peer reviewed; Journal article, 2019-07-05)
      Rheumatoid arthritis (RA) is a chronic autoimmune, inflammatory disease, characterized by synovitis in small- and medium-sized joints and, if not treated early and efficiently, joint damage, and destruction. RA is a ...

    • Cerebrospinal fluid proteome shows disrupted neuronal development in multiple sclerosis 

      Mosleth, Ellen Færgestad; Vedeler, Christian Alexander; Liland, Kristian Hovde; McLeod, Anette; Bringeland, Gerd Haga; Kroondijk, Liesbeth; Berven, Frode Steingrimsen; Lysenko, Artem; Rawlings, Christopher J.; El-Hajj Eid, Karim; Opsahl, Jill Anette; Gjertsen, Bjørn Tore; Myhr, Kjell-Morten; Gavasso, Sonia (Journal article; Peer reviewed, 2021-02-18)
      Despite intensive research, the aetiology of multiple sclerosis (MS) remains unknown. Cerebrospinal fluid proteomics has the potential to reveal mechanisms of MS pathogenesis, but analyses must account for disease ...

    • Early neurological worsening in acute ischaemic stroke patients 

      Nacu, Aliona; Bringeland, Gerd Haga; Khanevski, Andrej; Thomassen, Lars; Waje-Andreassen, Ulrike; Næss, Halvor (Peer reviewed; Journal article, 2016-01)
      Objectives: Neurological worsening in acute ischaemic stroke patients is common with significant morbidity and mortality. Aims: To determine the factors associated with early neurological worsening within the first 9 h ...

    • A mass cytometry receptor occupancy study of natalizumab therapy in multiple sclerosis 

      Bringeland, Gerd Haga (Doctoral thesis, 2020-06-05)
      Background: Natalizumab is a therapeutic antibody that effectively reduces disease activity in relapsing remitting multiple sclerosis (RRMS) by binding α4 integrin on leukocytes and preventing leukocyte migration into the ...

    • Optimization of receptor occupancy assays in mass cytometry: Standardization across channels with QSC beads 

      Bringeland, Gerd Haga; Bader, Lucius; Blaser, Nello; Budzinski, Lisa; Schulz, Axel R.; Mei, Henrik E.; Myhr, Kjell-Morten; Vedeler, Christian A.; Gavasso, Sonia (Peer reviewed; Journal article, 2019)
      Receptor occupancy, the ratio between amount of drug bound and amount of total receptor on single cells, is a biomarker for treatment response to therapeutic monoclonal antibodies. Receptor occupancy is traditionally ...

    • Wearing-off at the end of natalizumab dosing interval and risk of MS disease activity: A prospective 1-year follow-up study 

      Bringeland, Gerd Haga; Myhr, Kjell-Morten; Vedeler, Christian A.; Gavasso, Sonia (Journal article; Peer reviewed, 2020)
      Natalizumab effectively prevents disease activity in relapsing-remitting multiple sclerosis by binding α4 integrin and inhibiting leukocyte migration to the central nervous system. We recently reported an association between ...

    • Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy 

      Bringeland, Gerd Haga; Blaser, Nello; Myhr, Kjell-Morten; Vedeler, Christian A.; Gavasso, Sonia (Journal article; Peer reviewed, 2020-02)
      Objective: We aimed to investigate whether wearing-off symptoms at the end of the natalizumab dosing interval were associated with clinical and demographic patient characteristics or natalizumab receptor occupancy (RO) on ...